Clinical trials: Idiopathic Membranous Nephropathy
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney.
- Trial name
- PROMINENT (NCT06962800)
- Testing
- Felzartamab, Tacrolimus, Standard of Care IST
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Biogen
Mild Cognitive Impairment, Idiopathic Membranous Nephropathy
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
This study intends to apply prospective, open, single-center, randomized controlled study to evaluate the cognitive status of patients with Idiopathic membranous nephropathy and the influence of different treatment schemes on the…
- Trial name
- NCT06245707
- Testing
- prednisone,methylprednisone and cyclophosphamide, Rituximab
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Beijing Friendship Hospital
Membranous Nephropathy - PLA2R Induced
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower…
- Trial name
- NCT05679336
- Testing
- Rituximab, Cyclophosphamide, and Corticosteroids
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hyperspectral Imaging, Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined…
- Conditions
- Hyperspectral Imaging, Idiopathic Membranous Nephropathy, Cyclophosphamide
- Trial name
- NCT05850845
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 40 people
- Sponsor
- Qianfoshan Hospital
Nephrotic Syndrome, Proteinuria
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Background: Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood.
- Conditions
- Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease
- Trial name
- NCT00977977
- Testing
- Rituximab Infusion, Oral Cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Idiopathic Membranous Nephropathy
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy…
- Trial name
- NCT04154787
- Testing
- LNP023, Rituximab
- Where
- 18 sites in Argentina, China and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Primary Membranous Nephropathy
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the…
- Trial name
- NCT05668403
- Testing
- B007
- Where
- 6 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Idiopathic Membranous Nephropathy
Prognostic Model of TAC in the Treatment of MN
The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of tacrolimus.
- Trial name
- NCT05667922
- Testing
- Tacrolimus
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
Membranous Nephropathy
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
- Trial name
- NCT04652570
- Testing
- VB119
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tenet Medicines
Glomerulonephritis, Membranous
Rituximab in Refractory Primary Membranous Nephropathy
Primary membranous nephropathy (PMN), an autoimmune disease mostly associated with anti-phospholipase-A2-receptor (PLA2R) antibodies, is one of the most common causes of nephrotic syndrome in adults.
- Trial name
- NCT03880643
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Istanbul University
Glomerulonephritis, Membranous
Mycophenolate Mofetil in Membranous Nephropathy
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality.
- Trial name
- NCT00135967
- Testing
- mycophenolate mofetil orally 1000 mg twice a day (BID), prednisone 0,5 mg/kg orally on alternate days, intravenous (i.v.) methylprednisolone 1000 mg, total 9
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Membranous Nephropathy
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults.
- Trial name
- iRITUX (NCT06341205)
- Testing
- RiTUXimab Injection
- Where
- 14 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
This is an investigator initiated, single-arm, open-label, dose-escalation study to explore the preliminary efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the universal STAR-T…
- Trial name
- NCT07746453
- Testing
- Universal STAR-T Cell
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy, Kidney Transplant Recipients
MYTP01 for Immune-Mediated Diseases
The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for…
- Conditions
- IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy
- Trial name
- NCT07901764
- Testing
- MYTP01
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang Provincial People's Hospital